104 related articles for article (PubMed ID: 31278729)
1. Review: Patient-controlled transdermal 4-hydroxytamoxifen (4-OHT) vs. oral tamoxifen: A systematic review and meta analysis.
Sundralingam U; Khan TM; Elendran S; Muniyandy S; Palanisamy UD
Pak J Pharm Sci; 2019 May; 32(3):1121-1128. PubMed ID: 31278729
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.
Lee O; Page K; Ivancic D; Helenowski I; Parini V; Sullivan ME; Margenthaler JA; Chatterton RT; Jovanovic B; Dunn BK; Heckman-Stoddard BM; Foster K; Muzzio M; Shklovskaya J; Skripkauskas S; Kulesza P; Green D; Hansen NM; Bethke KP; Jeruss JS; Bergan R; Khan SA
Clin Cancer Res; 2014 Jul; 20(14):3672-82. PubMed ID: 25028506
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
4. Novel routes for administering chemoprevention: local transdermal therapy to the breasts.
Lee O; Khan SA
Semin Oncol; 2016 Feb; 43(1):107-115. PubMed ID: 26970129
[TBL] [Abstract][Full Text] [Related]
5. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Lee O; Ivancic D; Allu S; Shidfar A; Kenney K; Helenowski I; Sullivan ME; Muzzio M; Scholtens D; Chatterton RT; Bethke KP; Hansen NM; Khan SA
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1235-46. PubMed ID: 26560487
[TBL] [Abstract][Full Text] [Related]
6. Presurgical Oral Tamoxifen vs Transdermal 4-Hydroxytamoxifen in Women With Ductal Carcinoma In Situ: A Randomized Clinical Trial.
Khan SA; Mi X; Xu Y; Blanco LZ; Akasha AM; Pilewskie M; Degnim AC; AlHilli Z; Amin AL; Hwang ES; Guenther JM; Kocherginsky M; Benante K; Zhang S; Helland T; Hustad SS; Gursel DB; Mellgren G; Dimond E; Perloff M; Heckman-Stoddard BM; Lee O
JAMA Surg; 2023 Dec; 158(12):1265-1273. PubMed ID: 37870954
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer.
Sundralingam U; Chakravarthi S; Radhakrishnan AK; Muniyandy S; Palanisamy UD
Pharmaceutics; 2020 Aug; 12(9):. PubMed ID: 32854385
[TBL] [Abstract][Full Text] [Related]
8. Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status.
Zhong Q; Zhang C; Zhang Q; Miele L; Zheng S; Wang G
BMC Cancer; 2015 Sep; 15():625. PubMed ID: 26354796
[TBL] [Abstract][Full Text] [Related]
9. Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells.
Devulapally R; Sekar TV; Paulmurugan R
Mol Pharm; 2015 Jun; 12(6):2080-92. PubMed ID: 25880495
[TBL] [Abstract][Full Text] [Related]
10. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis.
Staley H; McCallum I; Bruce J
Breast; 2014 Oct; 23(5):546-51. PubMed ID: 25023044
[TBL] [Abstract][Full Text] [Related]
11. [Radiotherapy and tamoxifen facilitate breast-preserving treatment of ductal carcinoma in situ of the breast].
Sautter-Bihl ML
Strahlenther Onkol; 1999 Dec; 175(12):620-1. PubMed ID: 10633790
[No Abstract] [Full Text] [Related]
12. Postoperative tamoxifen for ductal carcinoma in situ.
Staley H; McCallum I; Bruce J
Cochrane Database Syst Rev; 2012 Oct; 10():CD007847. PubMed ID: 23076938
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: a meta-analysis of 2 randomized trials.
Petrelli F; Barni S
Radiother Oncol; 2011 Aug; 100(2):195-9. PubMed ID: 21411161
[TBL] [Abstract][Full Text] [Related]
15. Combination of anti-estrogenic therapy with radiation in breast cancer: simultaneous or sequential treatment?
Schmidberger H; Hermann RM; Hess CF; Emons G
Onkologie; 2005 May; 28(5):275-80. PubMed ID: 15867485
[TBL] [Abstract][Full Text] [Related]
16. [Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial].
Noël G; Mezziou M; Mazeron JJ
Cancer Radiother; 1999; 3(6):524-5. PubMed ID: 10630169
[No Abstract] [Full Text] [Related]
17. In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast.
Lee O; Ivancic D; Chatterton RT; Rademaker AW; Khan SA
Breast Cancer (Dove Med Press); 2011; 3():61-70. PubMed ID: 24367176
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
19. Novel iontophoretic administration method for local therapy of breast cancer.
Komuro M; Suzuki K; Kanebako M; Kawahara T; Otoi T; Kitazato K; Inagi T; Makino K; Toi M; Terada H
J Control Release; 2013 Jun; 168(3):298-306. PubMed ID: 23562634
[TBL] [Abstract][Full Text] [Related]
20. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients.
Sheth HR; Lord G; Tkaczuk K; Danton M; Lewis LM; Langenberg P; Lim CK; Flaws JA
J Womens Health (Larchmt); 2003 Oct; 12(8):799-808. PubMed ID: 14588130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]